AbbVie Earnings: Continued Impressive Demand for Skyrizi, Neuroscience Portfolio Support Growth

AbbVie reported robust Q2 results, with revenue up 6.6% to $15.4 billion and adjusted EPS growing 12.1% to $2.97, leading to raised full-year guidance. Strong demand for Skyrizi and Rinvoq successfully offset Humira's biosimilar erosion and drove immunology growth, complemented by a solid neuroscience performance, despite weakness in aesthetics. The extended patent protection for Skyrizi and Rinvoq through 2033 provides AbbVie significant runway to develop its pipeline and integrate strategic acquisitions like Capstan Therapeutics, positioning the company to mitigate future patent cliffs.

Analysis

AbbVie (ABBV) reported a strong second quarter, with revenue growing 6.6% to $15.4 billion and adjusted diluted EPS increasing 12.1% to $2.97, prompting an upward revision of its full-year guidance. The performance demonstrates the company's successful navigation of the Humira patent cliff, as robust sales from immunology drugs Skyrizi and Rinvoq have more than offset the revenue erosion from Humira biosimilars. This dynamic has enabled a return to top-line growth following a dip in 2023. Further strength is evident in the neuroscience portfolio, which is posting double-digit growth. However, a notable headwind persists in the aesthetics segment, where economic concerns and changing consumer trends are dampening performance. From a long-term perspective, the patent protections for Skyrizi and Rinvoq, which extend through 2033, provide a crucial decade-long window for pipeline development. AbbVie is actively utilizing this time, as evidenced by its acquisitions like Capstan Therapeutics and licensing deals for assets in high-growth areas like obesity, strategically positioning itself to address its next major patent cliff. Despite a 'High' uncertainty rating, the stock is considered fairly valued against a $184 fair value estimate.

Key Decisions for Investors

• Investors should recognize that AbbVie has effectively mitigated the immediate impact of the Humira patent expiration, with Skyrizi and Rinvoq now serving as the primary growth drivers for the medium term.
• It is prudent to monitor the performance of the aesthetics division, as continued weakness could offset gains in the core pharmaceutical segments and temper overall growth expectations.
• Long-term investors should track the progress of AbbVie's pipeline, particularly the integration of the Capstan Therapeutics acquisition and clinical developments in its obesity program, as these are key to de-risking the post-2033 outlook.
• Given that the stock is assessed as fairly valued, current levels may represent a reasonable entry point for a long-term hold, but investors should remain cognizant of the high uncertainty rating associated with future pipeline execution.